Holen Sie sich die Stockscreener-App
35.69
1.16%
0.41
Vorhandelsmarkt:
35.90
0.21
+0.59%
Schlusskurs vom Vortag:
$35.28
Offen:
$35.28
24-Stunden-Volumen:
1.08M
Relative Volume:
0.52
Marktkapitalisierung:
$3.80B
Einnahmen:
$741.17M
Nettoeinkommen (Verlust:
$104.65M
KGV:
40.78
EPS:
0.8752
Netto-Cashflow:
$162.57M
1W Leistung:
-1.46%
1M Leistung:
-11.06%
6M Leistung:
-48.55%
1J Leistung:
-36.26%
1-Tages-Spanne:
$34.93
$36.05
1-Wochen-Bereich:
$33.99
$36.47
52-Wochen-Spanne:
$28.66
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
35.69 | 3.75B | 741.17M | 104.65M | 162.57M | 0.8752 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-31 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Eingeleitet | UBS | Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead? - Zacks Investment Research
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics IncorporatedCORT - ChartMill
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Corcept Therapeutics (NASDAQ: CORT) Form 144 lists 20,000-share sale on 03/04/2026 - Stock Titan
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action - wjfw.com
Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
Corcept Therapeutics faces securities lawsuit over FDA rejection By Investing.com - Investing.com Canada
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
Corcept (CORT) CEO awarded 460,000 stock options in new grant - Stock Titan
Corcept Therapeutics (CORT) officer awarded stock options on 140,000 shares - Stock Titan
Corcept Therapeutics (CORT) CFO awarded stock options on 140,000 shares - Stock Titan
Corcept Therapeutics (CORT) CSO Hazel Hunt awarded 140,000 stock options - Stock Titan
Corcept (NASDAQ: CORT) grants CBO 140,000 options vesting over four years - Stock Titan
Investors of Corcept Therapeutics, Inc. (CORT) Seeking Recovery - The National Law Review
CORCEPT THERAPEUTICS INCORPORATED (CORT) DEADLINE ALERT Bernstein Liebhard LLP Reminds Corcept Therapeutics Incorporated Investors of Upcoming Deadline - ACCESS Newswire
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Beha - GlobeNewswire
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline - ChartMill
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated LawsuitCORT - PR Newswire
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - Financial Times
ARDT IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Ardent Health, Inc. Investors to Secure Counsel Before Important March 9 Deadline in Securities Class Action - GlobeNewswire Inc.
Shareholders who lost money in shares of Corcept - GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Corcept - GlobeNewswire
FinancialContentDeadline to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (CORT) is April 21, 2026Contact Kaplan Fox - FinancialContent
Deadline Approaching: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - FinancialContent
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, Inc. (NASDAQ - marketscreener.com
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
How Relacorilant Setback and Lawsuits Will Impact Corcept Therapeutics’ (CORT) Risk-Reward Profile - simplywall.st
Corcept Therapeutics Accused of Misleading Investors in Class Action - Intellectia AI
Corcept Therapeutics (CORT) Litigation: Hagens Berman - GlobeNewswire
Canaccord Genuity Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
Corcept Therapeutics Lawsuits And CRL Put Relacorilant Story Under Pressure - Yahoo Finance
What is Corcept Therapeutics Incorporated’s market positionJuly 2025 Summary & Safe Entry Point Identification - mfd.ru
CORCEPT THERAPEUTICS INCORPORATED (CORT) Stock, Price, News, Quotes, Forecast and Insights - MSN
Is Corcept Therapeutics (CORT) Pricing Reflect Its Sharp One Year Share Price Decline - Yahoo Finance
HC Wainwright Analysts Increase Earnings Estimates for CORT - MarketBeat
TD Asset Management Inc Grows Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
A Look At Corcept Therapeutics (CORT) Valuation After Relacorilant FDA Setback And New Lawsuits - simplywall.st
Corcept Therapeutics v. Teva Pharmaceuticals: Going Outside The Label To Show No Direct Infringement - Mondaq
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - mydailyrecord.com
Corcept (CORT) director exercises options and moves shares to family trusts - Stock Titan
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):